ESCMID: EVASG

Aims and objectives

The ESCMID Vaccine Study Group (EVASG) is at the forefront of vaccine research and education. Gathering experts aiming to promote advancement in the field of vaccination, covering public health to special populations, our mission is to:

Document the impact of vaccines
Assess perceptions and attitudes of the public towards vaccination
Map needs and develop guidelines to keep up with the emergence of new vaccines

Activities and resources

EVASG Newsletter, Fall 2023, 27 October 2023

Download

Impact of vaccination on the presence and severity of symptoms in hospitalized patients with an infection of the Omicron variant (B.1.1.529) of the SARS-CoV-2 (subvariant BA.1).

Beraud G, Bouetard L, Civljak R, Michon J, Tulek N, Lejeune S, Millot R, Garchet-Beaudron A, Lefebvre M, Veliko P, Festou B, Abgrall S, Lizatovic I K, Baldolli A, Esme H, Blanch S, Froidevaux G, Kapincheva N, Faucher JF, Duvnjak M, Afşar E, Švitek L, Yarimoglu S, Yarimoglu R, Janssen C, Epaulard O, on behalf of EVASG. Clin Microbiol Infect. 2023;29(5):642–650.

Go to publication

Exclusion of older adults and immunocompromised individuals in influenza, pneumococcal and COVID-19 vaccine trials before and after the COVID-19 pandemic.

Bukan K, Pearce-Slade T, Eiberg M, Tinelli M, Yahav D, Tuells J, Epaulard O, Holler JG, Roed C, Søborg C, Jensen Stæhr JU, Barrella Harboe Z. Aging Clin Exp Res. 2023;35(5):917–923.

Go to publication

Measles in the 21st century: Is eradication possible and how?

Post-graduate course

Go to courses